Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Vireo Growth Inc. (VREOF)
USD10.00
-0.02 (-0.16%)
US OTC Healthcare Drug Manufacturers - Specialty & Generic
Address
207 South 9th Street 55402
Minneapolis, MN, US
Minneapolis, MN, US
CEO
John Mazarakis
Website
vireogrowth.com
IPO
2019-03-18
CIK 1771706 ISIN CA92767B2049
Description
Vireo Growth Inc. operates as a cannabis company that cultivates, manufactures, processes, and distributes medical and adult-use cannabis products in Maryland, Minnesota, Missouri, Nevada, New York, and Utah. It sells cannabis products through a network of retail dispensaries and distributors. The company was formerly known as Goodness Growth Holdings, Inc. and changed its name to Vireo Growth Inc. in July 2024. Vireo Growth Inc. was incorporated in 2004 and is headquartered in Minneapolis, Minnesota.
News Sentiment (7d)
Based on only 2 articles — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD10.00
-0.02 (-0.16%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
11.6K
Beta
0.23
Float Shares
685.99M
Free Float %
63.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.75% | -1.71% | +3.20% | -20.98% | -28.67% | -34.25% | +6.05% | +135.67% | -80.75% | -90.09% | -90.09% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Hold
Price Targets & DCF
Current price
10.00
Low
0.45
-95.5%
Consensus
0.45
-95.5%
Median
0.45
-95.5%
High
0.45
-95.5%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
0.45
-95.5%
|
Quality scores
Altman Z-Score
0.35
Distress
Piotroski F-Score
5 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+170.4% ★ Q1'26: +332.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+41.1% ★ Q1'26: +0.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-24.7% Q1'26: +1.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-3.6% Q1'26: +0.0% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-1.9% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+307.3% Q1'26: +294,461.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×24.69× Q1'26: 0.72× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
99.38M
est: 98.26M (+1.1%)
|
268.77M
est: 259.18M (+3.7%)
|
631.57M
613.83M – 649.30M
+143.7% YoY
|
861.60M
837.41M – 885.79M
+36.4% YoY
|
911.00M
885.42M – 936.58M
+5.7% YoY
|
| EBITDA |
17.65M
est: -443.1K (+4,083.6%)
|
12.30M
est: -1.17M (+1,152.5%)
|
-2.85M
-2.93M – -2.77M
-143.7% YoY
|
-3.89M
-3.99M – -3.78M
-36.4% YoY
|
-4.11M
-4.22M – -3.99M
-5.7% YoY
|
| EBIT |
14.29M
est: -5.42M (+363.8%)
|
-9.66M
est: -14.29M (+32.4%)
|
-34.82M
-35.80M – -33.85M
-143.7% YoY
|
-47.51M
-48.84M – -46.17M
-36.4% YoY
|
-50.23M
-51.64M – -48.82M
-5.7% YoY
|
| Net Income |
-28.01M
est: -73.47M (+61.9%)
|
-68.11M
est: -44.08M (-54.5%)
|
29.39M
28.32M – 30.46M
+166.7% YoY
|
51.43M
49.55M – 53.31M
+75.0% YoY
|
58.78M
56.63M – 60.92M
+14.3% YoY
|
| SGA |
31.69M
est: 44.42M (-28.7%)
|
99.85M
est: 117.17M (-14.8%)
|
285.52M
277.50M – 293.54M
+143.7% YoY
|
389.51M
378.58M – 400.45M
+36.4% YoY
|
411.85M
400.28M – 423.41M
+5.7% YoY
|
| EPS |
-0.16
est: -0.10 (-60.0%)
|
-0.09
est: -0.06 (-57.2%)
|
0.04
0.04 – 0.04
+166.7% YoY
|
0.07
0.07 – 0.07
+75.0% YoY
|
0.08
0.08 – 0.08
+14.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
131.53M
OE per share TTM
0.13
Owner's Yield
31.24%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
93.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | AdvisorShares Pure US Cannabis ETF MSOS | 0.22% | 2.00M | 0.81% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.60
Neutral
Ratio by volume
0.93
Neutral
Buys
6
Sells
10
Shares acquired
16.00M
Shares disposed
17.13M
Cash buys
—
Cash sales
—
Net activity
-1,139,574
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-03 | Steiner Michael L. | Director | — | — | Subordinate Voting Shares | 0 | 0.00 | — | 1,675,903 | D | ↗ |
| 2025-12-29 | Shimpa Amber Holly | Officer | F-InKind | D | Subordinate Voting Shares | 126,666 | 0.60 | 76.0K | 1,119,965 | D | ↗ |
| 2025-12-29 | Mazarakis John | Director / Officer | F-InKind | D | Subordinate Voting Shares | 3,502,150 | 0.67 | 2.35M | 9,833,737 | D | ↗ |
| 2025-12-29 | Macdonald Tyson | Officer | F-InKind | D | Subordinate Voting Shares | 481,554 | 0.53 | 255.2K | 7,416,021 | D | ↗ |
| 2025-12-29 | Kingsley Kyle Eugene | Director / Officer | F-InKind | D | Subordinate Voting Shares | 276,509 | 0.60 | 165.9K | 14,206,363 | D | ↗ |
| 2025-12-29 | Apfelbaum Sean Michael | Officer | F-InKind | D | Subordinate Voting Shares | 62,145 | 0.64 | 39.8K | 137,855 | D | ↗ |
| 2025-12-17 | Mazarakis John | Director / Officer | A-Award | A | Subordinate Voting Shares | 5,700,000 | 0.85 | 4.85M | 10,937,736 | D | ↗ |
| 2025-12-17 | Macdonald Tyson | Officer | A-Award | A | Subordinate Voting Shares | 2,850,000 | 0.85 | 2.42M | 6,708,868 | D | ↗ |
| 2025-11-13 | Mazarakis John | Director / Officer | A-Award | A | Subordinate Voting Shares | 2,037,736 | 0.00 | — | 5,237,736 | D | ↗ |
| 2025-11-13 | Macdonald Tyson | Officer | A-Award | A | Subordinate Voting Shares | 1,018,868 | 0.00 | — | 3,858,868 | D | ↗ |
| 2025-09-30 | Apfelbaum Sean Michael | Officer | M-Exempt | D | Restricted stock units | 200,000 | 0.00 | — | 0 | D | ↗ |
| 2025-08-31 | Duxbury Joseph | Officer | A-Award | A | Restricted stock units | 360,000 | 0.00 | — | 360,000 | D | ↗ |
| 2025-08-31 | Apfelbaum Sean Michael | Officer | A-Award | A | Restricted stock units | 200,000 | 0.00 | — | 200,000 | D | ↗ |
| 2025-08-07 | Apfelbaum Sean Michael | Officer | — | — | Subordinate Voting Shares | 0 | 0.00 | — | 0 | D | ↗ |
| 2025-06-13 | Shimpa Amber Holly | Officer | C-Conversion | D | Multiple Voting Shares | 8,521 | 0.00 | — | 0 | D | ↗ |
| 2025-05-09 | Mazarakis John | Director / Officer | A-Award | A | Restricted stock units | 19,000,000 | 0.00 | — | 19,000,000 | D | ↗ |
| 2025-05-09 | Macdonald Tyson | Officer | A-Award | A | Restricted stock units | 9,500,000 | 0.00 | — | 9,500,000 | D | ↗ |
| 2025-01-17 | Nordquist Judd Theodore | Director | A-Award | A | Stock options (right to buy) | 53,052 | 0.49 | 26.0K | 53,052 | D | ↗ |
| 2025-01-17 | Mancebo Victor E. | Director | A-Award | A | Restricted stock units | 44,643 | 0.00 | — | 44,643 | D | ↗ |
| 2025-01-17 | Hussey Ross Michael | Director | A-Award | A | Restricted stock units | 44,643 | 0.00 | — | 44,643 | D | ↗ |
| 2024-12-17 | Mazarakis John | Director / Officer | A-Award | A | Subordinate Voting Shares | 3,200,000 | 0.00 | — | 3,200,000 | D | ↗ |
| 2024-12-17 | Macdonald Tyson | Officer | — | — | Subordinate Voting Shares | 0 | 0.00 | — | 0 | D | ↗ |
| 2024-12-17 | Kingsley Kyle Eugene | Officer | A-Award | A | Subordinate Voting Shares | 7,000,000 | 0.00 | — | 13,541,100 | D | ↗ |
| 2024-12-17 | Duxbury Joseph | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-10-10 | Shimpa Amber Holly | Officer | A-Award | A | Stock Option (right to buy) | 1,000,000 | 0.48 | 480.0K | 1,000,000 | D | ↗ |
| 2024-10-10 | Rosen Joshua | Director / Officer | A-Award | A | Subordinate Voting Shares | 500,000 | 0.00 | — | 500,000 | D | ↗ |
| 2024-10-10 | Duxbury Joseph | Officer | — | — | Subordiate Voting Shares | 0 | 0.00 | — | 3,000 | D | ↗ |
| 2024-10-09 | Rosen Joshua | Director / Officer | A-Award | A | Stock Option (right to buy) | 500,000 | 0.50 | 250.0K | 500,000 | D | ↗ |
| 2024-08-23 | Rosen Joshua | Director / Officer | A-Award | A | Stock Option (right to buy) | 250,000 | 0.47 | 117.5K | 250,000 | D | ↗ |
| 2024-08-23 | Nordquist Judd Theodore | Director | A-Award | A | Restricted stock units | 418,696 | 0.00 | — | 418,696 | D | ↗ |
| 2024-08-23 | Mancebo Victor E. | Director | A-Award | A | Restricted stock units | 418,696 | 0.00 | — | 418,696 | D | ↗ |
| 2024-08-23 | Hussey Ross Michael | Director | A-Award | A | Restricted stock units | 418,696 | 0.00 | — | 418,696 | D | ↗ |
| 2024-06-14 | Chicago Atlantic Credit Opportunities, LLC | 10% Owner | P-Purchase | A | Subordinate Voting Shares | 1,300,078 | 0.54 | 700.0K | 1,301,216 | — | ↗ |
| 2024-05-31 | Rosen Joshua | Director / Officer | A-Award | A | Subordinate Voting Shares | 121,625 | 0.00 | — | 204,462 | — | ↗ |
| 2023-12-21 | Shimpa Amber Holly | Officer | A-Award | A | Option | 750,000 | 0.25 | 187.5K | 1,320,787 | — | ↗ |
| 2023-07-31 | Kingsley Kyle Eugene | Director / Officer | C-Conversion | A | Subordinate Voting Shares | 6,541,100 | 0.00 | — | 6,541,100 | — | ↗ |
| 2023-06-07 | Schroeder J Michael | Officer | A-Award | A | Stock Options | 619,907 | 0.18 | 108.9K | 1,690,075 | — | ↗ |
| 2023-06-07 | Heller John Andrew | Officer | A-Award | A | Stock Option | 1,602,829 | 0.18 | 281.6K | 1,973,541 | — | ↗ |
| 2023-05-31 | Chicago Atlantic Credit Opportunities, LLC | 10% Owner | — | I | Subordinate Voting Shares | 0 | 0.00 | — | 1,138 | — | ↗ |
| 2023-04-28 | Chicago Atlantic Credit Opportunities, LLC | 10% Owner | — | D | 2023 Warrants | 4,894,561 | 0.15 | 709.7K | 0 | — | ↗ |
| 2023-01-04 | Kingsley Kyle Eugene | Director / Officer | A-Award | A | Stock Options | 5,100,821 | 0.00 | — | 6,405,578 | — | ↗ |
| 2022-12-14 | Shimpa Amber Holly | Director / Officer | A-Award | A | Restricted Stock Units | 267,510 | 0.00 | — | 371,001 | — | ↗ |
| 2022-12-14 | Schroeder J Michael | Director | A-Award | A | Restricted Stock Units | 257,221 | 0.00 | — | 356,732 | — | ↗ |
| 2022-12-14 | Rosen Joshua | Director | A-Award | A | Stock Options | 79,468 | 0.30 | 23.8K | 119,453 | — | ↗ |
| 2022-12-14 | Peters Patrick | Director | A-Award | A | Stock Options | 247,131 | 0.00 | — | 1,001,522 | — | ↗ |
| 2022-12-14 | Nordquist Judd Theodore | Director | A-Award | A | Restricted Stock Units | 85,742 | 0.00 | — | 118,912 | — | ↗ |
| 2022-12-14 | Mancebo Victor E. | Director | A-Award | A | Restricted Stock Units | 85,742 | 0.00 | — | 118,912 | — | ↗ |
| 2022-12-14 | Heller John Andrew | Director / Officer | A-Award | A | Restricted Stock Units | 308,665 | 0.00 | — | 428,078 | — | ↗ |
| 2022-12-14 | GRAYSON CHELSEA A | Director | A-Award | A | Restricted Stock Options | 102,976 | 0.00 | — | 608,297 | — | ↗ |
| 2022-03-15 | Shimpa Amber Holly | Director / Officer | A-Award | A | Stock Options | 249,503 | 0.00 | — | 249,503 | — | ↗ |
| 2022-03-15 | Schroeder J Michael | Officer | A-Award | A | Restricted Stock Units | 99,511 | 0.00 | — | 99,511 | — | ↗ |
| 2022-03-15 | Rosen Joshua | Director | A-Award | A | Stock Options | 39,985 | 0.00 | — | 39,985 | — | ↗ |
| 2022-03-15 | Peters Patrick | Director | A-Award | A | Stock Options | 191,926 | 0.00 | — | 191,926 | — | ↗ |
| 2022-03-15 | Ocasio Christian Gonzales | Director / Officer | A-Award | A | Restricted Stock Units | 99,511 | 0.00 | — | 99,511 | — | ↗ |
| 2022-03-15 | Nordquist Judd Theodore | Director | A-Award | A | Restricted Stock Units | 33,170 | 0.00 | — | 33,170 | — | ↗ |
| 2022-03-15 | Mancebo Victor E. | Director | A-Award | A | Stock Options | 59,988 | 0.00 | — | 59,988 | — | ↗ |
| 2022-03-15 | Kingsley Kyle Eugene | Director / Officer | A-Award | A | Restricted Stock Units | 262,708 | 0.00 | — | 262,708 | — | ↗ |
| 2022-03-15 | Hussey Ross Michael | Director | A-Award | A | Stock Options | 60,105 | 0.00 | — | 60,105 | — | ↗ |
| 2022-03-15 | Heller John Andrew | Director / Officer | A-Award | A | Stock Units | 287,888 | 0.00 | — | 287,888 | — | ↗ |
| 2022-03-15 | GRAYSON CHELSEA A | Director | A-Award | A | Stock Options | 157,832 | 0.00 | — | 157,832 | — | ↗ |
| 2022-03-15 | Dahmer Stephen | Director / Officer | A-Award | A | Restricted Stock Units | 99,511 | 0.00 | — | 99,511 | — | ↗ |
| 2021-08-12 | Rosen Joshua | Director | — | I | Subordinate Voting Shares | 0 | 0.00 | — | 730,014 | — | ↗ |
| 2021-06-11 | Nordquist Judd Theodore | Director | A-Award | A | Stock Options | 39,300 | 2.32 | 91.2K | 39,300 | — | ↗ |
| 2021-06-11 | Mancebo Victor E. | Director | A-Award | A | Stock Options | 6,550 | 2.32 | 15.2K | 6,550 | — | ↗ |
| 2021-06-11 | Hussey Ross Michael | Director | A-Award | A | Stock Options | 72,049 | 2.32 | 167.2K | 72,049 | — | ↗ |
| 2021-06-11 | GRAYSON CHELSEA A | Director | A-Award | A | Stock Options | 39,300 | 2.32 | 91.2K | 39,300 | — | ↗ |
| 2021-03-25 | Chicago Atlantic Credit Opportunities, LLC | 10% Owner | — | I | 2021 Warrants | 670,620 | 2.66 | 1.78M | 0 | — | ↗ |
| 2021-01-15 | Mancebo Victor E. | Director | — | D | Super Voting Shares | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-01-04 | Shimpa Amber Holly | Director / Officer | — | D | Stock Options | 300,048 | 0.19 | 57.0K | 0 | — | ↗ |
| 2021-01-04 | Schroeder J Michael | Officer | — | — | Stock Options | 400,000 | 1.19 | 476.0K | 0 | D | ↗ |
| 2021-01-04 | Peters Patrick | Officer | — | D | Stock Options | 62,465 | 1.13 | 70.6K | 0 | — | ↗ |
| 2021-01-04 | Ocasio Christian Gonzales | Officer | — | D | Stock Options | 500,000 | 1.19 | 595.0K | 0 | — | ↗ |
| 2021-01-04 | Nordquist Judd Theodore | Director | — | D | Stock Options | 301,189 | 0.77 | 231.9K | 0 | — | ↗ |
| 2021-01-04 | Kingsley Kyle Eugene | Director / Officer / 10% Owner | — | D | Stock Options | 600,096 | 0.33 | 198.0K | 0 | — | ↗ |
| 2021-01-04 | Hussey Ross Michael | Director | — | D | Multiple Voting Shares | 0 | 0.00 | — | 16,803 | — | ↗ |
| 2021-01-04 | Heller John Andrew | Officer | — | D | Stock Options | 1,314,941 | 0.77 | 1.01M | 0 | — | ↗ |
| 2021-01-04 | GRAYSON CHELSEA A | Director | — | D | Stock Options | 308,189 | 0.77 | 237.3K | 0 | — | ↗ |
| 2021-01-04 | Dahmer Stephen | Officer | — | D | Stock Options | 900,145 | 0.33 | 297.0K | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-18.9K
Shares Outstanding
1.08B
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | John Mazarakis Chief Executive Officer and Co-Executive Chairman | 1.00 | 2.30M | 17.73M | — | — | — | 20.03M | 88.50% | ↗ |
| 2 | 2025 | Tyson Macdonald Chief Financial Officer | 500.0K | 1.15M | 8.62M | — | — | — | 10.27M | 83.91% | ↗ |
| 3 | 2025 | Sean Apfelbaum General Counsel | 145.8K | 300.0K | 128.8K | — | — | — | 574.6K | 22.41% | ↗ |
| 4 | 2024 | Dr. Kyle E. Kingsley Co-Executive Chairman | 270.0K | — | 1.75M | — | — | — | 2.02M | 86.63% | ↗ |
| 5 | 2024 | Joshua N. Rosen Former Chief Executive Officer | 300.0K | — | 471.6K | 320.3K | — | — | 1.09M | 72.53% | ↗ |
| 6 | 2024 | Tyson Macdonald Chief Financial Officer | 15.4K | — | 800.0K | — | — | — | 815.4K | 98.11% | ↗ |
| 7 | 2024 | John Mazarakis Chief Executive Officer and Co-Executive Chairman | 1.00 | — | 800.0K | — | — | — | 800.0K | 100.00% | ↗ |
| 8 | 2024 | Amber Shimpa President and Corporate Secretary | 275.0K | — | — | 402.2K | — | — | 677.2K | 59.39% | ↗ |
| 9 | 2024 | Patrick Peters Former Executive Vice President of Retail | 102.3K | — | — | 68.2K | — | — | 170.5K | 39.99% | ↗ |
| 10 | 2024 | Joseph Duxbury Chief Accounting Officer and Former Interim Chief Financial Officer | 165.8K | — | — | — | — | — | 165.8K | 0.00% | ↗ |
| 11 | 2023 | Dr. Kyle E. Kingsley Former Chief Executive Officer and Executive Chair of the Board | 275.0K | — | — | 682.3K | — | 176.00 | 957.4K | 71.26% | ↗ |
| 12 | 2023 | Dr. Kyle E. Kingsley Co-Executive Chairman | 275.0K | — | — | 682.3K | — | 176.00 | 957.4K | 71.26% | ↗ |
| 13 | 2023 | John A. Heller Former Chief Financial Officer | 340.0K | — | — | 215.0K | — | 176.00 | 555.2K | 38.73% | ↗ |
| 14 | 2023 | Amber Shimpa President and Corporate Secretary | 260.0K | — | — | 164.1K | — | 176.00 | 424.2K | 38.67% | ↗ |
| 15 | 2023 | J. Michael Schroeder Former General Counsel and Chief Compliance Officer | 250.0K | — | — | 87.9K | — | 176.00 | 338.0K | 25.99% | ↗ |
| 16 | 2023 | Joshua N. Rosen Former Chief Executive Officer | 300.0K | — | — | — | — | 176.00 | 300.2K | 0.00% | ↗ |
| 17 | 2023 | Joshua N. Rosen Chief Executive Officer and Interim Chief Financial Officer | 300.0K | — | — | — | — | 176.00 | 300.2K | 0.00% | ↗ |
| 18 | 2023 | Patrick Peters Executive Vice President of Retail | 200.0K | — | — | — | — | 176.00 | 200.2K | 0.00% | ↗ |
| 19 | 2023 | Patrick Peters Former Executive Vice President of Retail | 200.0K | — | — | — | — | 176.00 | 200.2K | 0.00% | ↗ |
| 20 | 2022 | Dr. Kyle E. Kingsley Former Chief Executive Officer and Executive Chair of the Board | 360.0K | — | 672.4K | 558.4K | — | 176.00 | 1.59M | 77.36% | ↗ |
| 21 | 2022 | John A. Heller Former Chief Financial Officer | 300.0K | — | 305.7K | 269.7K | — | 176.00 | 875.5K | 65.71% | ↗ |
| 22 | 2022 | Amber Shimpa President and Corporate Secretary | 260.0K | — | 264.9K | 233.7K | — | 176.00 | 758.8K | 65.71% | ↗ |
| 23 | 2022 | Joshua N. Rosen Chief Executive Officer and Interim Chief Financial Officer | 11.5K | — | 49.2K | 528.1K | — | 65.8K | 654.6K | 88.19% | ↗ |
| 24 | 2021 | Dr. Kyle E. Kingsley Chief Executive Officer | 360.0K | — | — | — | — | 176.00 | 360.2K | 0.00% | ↗ |
| 25 | 2021 | John A. Heller Chief Financial Officer | 300.0K | — | — | — | — | 176.00 | 300.2K | 0.00% | ↗ |
| 26 | 2021 | Christian Gonzalez Chief Operating Officer | 250.0K | — | — | — | — | 176.00 | 250.2K | 0.00% | ↗ |
| 27 | 2020 | John Heller Chief Financial Officer | 133.3K | — | — | 827.2K | — | 176.00 | 960.8K | 86.10% | ↗ |
| 28 | 2020 | John A. Heller Chief Financial Officer | 133.3K | — | — | 827.2K | — | 176.00 | 960.8K | 86.10% | ↗ |
| 29 | 2020 | Christian Gonzalez Chief Operating Officer | 217.2K | — | — | 486.8K | — | — | 703.9K | 69.15% | ↗ |
| 30 | 2020 | Dr. Kyle E. Kingsley Chief Executive Officer | 295.3K | — | — | — | — | 176.00 | 295.4K | 0.00% | ↗ |
| 31 | 2019 | Dr. Kyle E. Kingsley Chief Executive Officer | 360.0K | — | — | — | — | 176.00 | 360.2K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| John Michael Mazarakis | CEO & Co-Executive Chairman | 2M | male |
| J. Tyson Macdonald | Chief Financial Officer | 2M | male |
| James Tyson Macdonald | Chief Financial Officer | 2M | male |
| Sean Michael Apfelbaum | General Counsel & Corporate Secretary | 641.2K | male |
| Amber H. Shimpa | President & CEO of Vireo Health of Minnesota LLC | 275.0K | female |
| Kyle E. Kingsley | Founder & Co-Executive Chairman | 260.0K | — |
| Joseph Duxbury | Chief Accounting Officer | 165.8K | male |
| Brandon Van Asten | Vice President of Finance & Controller | — | — |
| Nicole Stanton | Outside General Counsel | — | — |
| Cory Azzalino | CEO of Vireo's California Business | — | male |
| Aaron Garrido | Vice President & Chief of Staff | — | — |
| Eric Greenbaum | Chief Scientific Officer | — | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VREOF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
